【诺和诺德Ozempic显著改善糖尿病合并外周动脉疾病患者行走能力】在美国心脏病学会(ACC)2025年会上,诺和诺德宣布STRIDEⅢ期试验结果达到主要终点。试验显示,与安慰剂组相比,使用Ozempic(每周注射一次司美格鲁肽1.0毫克)52周后,Ⅱ型糖尿病合并外周动脉疾病患者在陡坡行走测试中最大步行距离提高13%。研究成果同步发表于《柳叶刀》期刊。

金融界
29 Mar
在美国心脏病学会(ACC)2025年会上,诺和诺德宣布STRIDEⅢ期试验结果达到主要终点。试验显示,与安慰剂组相比,使用Ozempic(每周注射一次司美格鲁肽1.0毫克)52周后,Ⅱ型糖尿病合并外周动脉疾病患者在陡坡行走测试中最大步行距离提高13%。研究成果同步发表于《柳叶刀》期刊。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10